Affimed N.V. (AFMD)’s Financial Results Comparing With Fortress Biotech Inc. (NASDAQ:FBIOP)

We are comparing Affimed N.V. (NASDAQ:AFMD) and Fortress Biotech Inc. (NASDAQ:FBIOP) on their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Affimed N.V. 3 0.00 N/A -0.37 0.00
Fortress Biotech Inc. 19 4.13 N/A -1.94 0.00

In table 1 we can see Affimed N.V. and Fortress Biotech Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 has Affimed N.V. and Fortress Biotech Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Affimed N.V. 0.00% -43.9% -26.7%
Fortress Biotech Inc. 0.00% 0% 0%

Analyst Recommendations

In next table is shown Affimed N.V. and Fortress Biotech Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Affimed N.V. 0 0 1 3.00
Fortress Biotech Inc. 0 0 0 0.00

Affimed N.V.’s upside potential currently stands at 171.19% and an $8 consensus price target.

Institutional and Insider Ownership

Affimed N.V. and Fortress Biotech Inc. has shares owned by institutional investors as follows: 41.8% and 0%. About 8.15% of Affimed N.V.’s share are owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Affimed N.V. -3.92% -10.68% 0.29% -15.52% 49.13% 10.29%
Fortress Biotech Inc. 2.04% 6.99% 6.36% 26.98% -11.6% 39%

For the past year Affimed N.V. has weaker performance than Fortress Biotech Inc.


Fortress Biotech Inc. beats on 5 of the 8 factors Affimed N.V.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD AndersonÂ’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.